\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ bilateral\\ hip\\ pain\\ upon\\ standing\\ and\\ walking\\.\\ pt\\ is\\ ttp\\ along\\ hip\\ joints\\ bilaterally\\.\\ pt\\ has\\ longstanding\\ pain\\ with\\ worsening\\ in\\ his\\ hip\\ pain\\ recently\\.\ \(0\)\
\-\ treatment\\ options\\ for\\ avascular\\ necrosis\\ of\\ the\\ femoral\\ heads\\ include\\ conservative\\ management\\,\\ total\\ hip\\ replacement\\,\\ core\\ decomprssion\\ with\\ or\\ without\\ bone\\ grafting\\ and\\ osteotomy\\.\\ \\ \ \(0\)\
\-\ this\\ patient\\ received\\ a\\ total\\ right\\ hip\\ arthroplasty\\ with\\ potential\\ replacement\\ of\\ left\\ hip\\ in\\ future\\.\ \(0\)\
\-\ frontal\\ and\\ frog\\ leg\\ films\\ of\\ both\\ hip\\ joints\\ revealed\\ extensive\\ degenerative\\ changes\\ on\\ the\\ bilateral\\ femoral\\ heads\\ and\\ acetabula\\.\\ acetabula\\ demonstrate\\ sclerosis\\ and\\ associated\\ osteophyte\\ and\\ subchondral\\ cyst\\ formation\\.\\ the\\ bilateral\\ femoral\\ heads\\ demonstrate\\ extensive\\ osteoarthritic\\ changes\\ with\\ sclerosis\\,\\ cyst\\ formation\\,\\ bilateral\\ ring\\ osteophytes\\ and\\ some\\ mild\\ flattening\\ of\\ the\\ femoral\\ heads\\.\\ \ \(0\)\
\-\ coronal\\ t1\\ and\\ t2\\ mri\\:\\ t1\\ and\\ t2\\ mri\\ revealed\\ extensive\\ degenerative\\ changes\\ on\\ the\\ bilateral\\ femoral\\ heads\\ and\\ acetabula\\.\\ there\\ is\\ high\\ signal\\ intensity\\ degenerative\\ edema\\ of\\ the\\ femoral\\ heads\\ on\\ t2\\.\\ superior\\ acetabula\\ demonstrate\\ low\\ signal\\ intensity\\ on\\ t1\\ and\\ associated\\ osteophyte\\ and\\ subchondral\\ cyst\\ formation\\.\\ the\\ bilateral\\ femoral\\ heads\\ demonstrate\\ extensive\\ osteoarthritic\\ changes\\ with\\ sclerosis\\,\\ cyst\\ formation\\,\\ bilateral\\ ring\\ osteophytes\\ and\\ some\\ mild\\ flattening\\ of\\ the\\ femoral\\ heads\\.\\ there\\ are\\ small\\ areas\\ of\\ abnormal\\ signal\\ to\\ suggest\\ avascular\\ necrosis\\.\ \(0\)\
\-\ avascular\\ necrosis\\ of\\ femoral\\ heads\\ bilaterally\\ with\\ associated\\ osteoarthritic\\ changes\\.\ \(0\)\
\-\ secondary\\ osteoarthritis\\ from\\ avascular\\ necrosis\ \(0\)\
\-\ primary\\ osteoarthritis\ \(4\)\
\-\ patient\\ is\\ a\\ 49\\ year\\ old\\ african\\ american\\ male\\ with\\ a\\ history\\ of\\ sarcoidosis\\,\\ sinusitis\\ with\\ intermittent\\ steroid\\ treatment\\ that\\ presents\\ with\\ several\\ years\\ of\\ bilateral\\ hip\\ pain\\.\ \(0\)\
\-\ avn\\ most\\ often\\ occurs\\ during\\ the\\ fourth\\ or\\ fifth\\ decade\\ of\\ life\\ and\\ is\\ bilateral\\ in\\ 55\\%\\ of\\ cases\\.\\ \\ the\\ etiology\\ for\\ avn\\ of\\ the\\ femoral\\ heads\\ is\\ vast\\ and\\ includes\\ trauma\\,\\ hemoglobinopathies\\,\\ caisson\\ disease\\,\\ local\\ infiltrative\\ diseases\\ such\\ as\\ gaucher\\ disease\\,\\ hypercortisolism\\,\\ alcohol\\,\\ pancreatitis\\,\\ renal\\ failure\\,\\ cigarteet\\ smoking\\,\\ collagen\\ vascular\\ diseasese\\,\\ congenital\\ diseases\\ such\\ as\\ scfe\\ and\\ legg\\-calvep\\-perthe\\,\\ fabry\\,\\ giant\\ cell\\ arteritis\\,\\ gout\\,\\ hemodialysis\\,\\ hld\\,\\ hyperparathyroidism\\,\\ pregnancy\\,\\ sle\\,\\ and\\ idiopathic\\.\\ the\\ most\\ common\\ cause\\ of\\ bilateral\\ avn\\ is\\ steroid\\ use\\,\\ even\\ for\\ short\\ periods\\.\\ our\\ patient\\ had\\ a\\ history\\ of\\ stage\\ i\\ sarcoid\\ disease\\ that\\ was\\ untreated\\.\\ \\ the\\ etiology\\ of\\ this\\ patient\\'s\\ bilateral\\ avn\\ of\\ the\\ femoral\\ head\\ is\\ unclear\\.\\ \\ there\\ is\\ no\\ case\\ report\\ of\\ a\\ link\\ between\\ sarcoid\\ and\\ avn\\.\\ the\\ patient\\ did\\ however\\ have\\ chronic\\ recurrent\\ bouts\\ of\\ sinusitis\\ that\\ required\\ steroids\\.\\ \\ he\\ received\\ both\\ fluticasone\\ and\\ oral\\ prednisone\\ for\\ short\\ periods\\ during\\ these\\ recurrent\\ attacks\\ of\\ sinusitis\\.\\ \\ this\\ appears\\ to\\ be\\ one\\ possible\\ etiology\\ of\\ his\\ avn\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ heads\\:\\ 0\\.11159336776379554\ \(0\)\
\-\ femoral\\:\\ 0\\.07707107367043502\ \(0\)\
\-\ avn\\:\\ 0\\.07591913075172489\ \(0\)\
\-\ hip\\:\\ 0\\.058687454691576865\ \(0\)\
\-\ acetabula\\:\\ 0\\.058069628295574674\ \(0\)\
\-\ bilateral\\:\\ 0\\.04916378237598897\ \(0\)\
\-\ avascular\\:\\ 0\\.0405572806878723\ \(0\)\
\-\ osteoarthritic\\:\\ 0\\.03830913792717888\ \(0\)\
\-\ sinusitis\\:\\ 0\\.03196756948098237\ \(0\)\
\-\ formation\\:\\ 0\\.030407339597172095\ \(0\)\
\-\ extensive\\:\\ 0\\.02945996312455815\ \(0\)\
\-\ necrosis\\:\\ 0\\.029078454426247454\ \(0\)\
\-\ changes\\:\\ 0\\.026390603192188153\ \(0\)\
\-\ periods\\:\\ 0\\.02604711078330481\ \(0\)\
\-\ degenerative\\:\\ 0\\.025046612077740477\ \(0\)\
\-\ etiology\\:\\ 0\\.023385914176944005\ \(0\)\
\-\ osteophyte\\:\\ 0\\.02333759069958768\ \(0\)\
\-\ osteophytes\\:\\ 0\\.022097581766605867\ \(0\)\
\-\ flattening\\:\\ 0\\.020071704054339768\ \(0\)\
\-\ sclerosis\\:\\ 0\\.019844710560946194\ \(0\)\
\-\ cyst\\:\\ 0\\.019796302896776745\ \(0\)\
\-\ steroid\\:\\ 0\\.019445919529147968\ \(0\)\
\-\ subchondral\\:\\ 0\\.01933097018827658\ \(0\)\
\-\ decomprssion\\:\\ 0\\.018998962120617455\ \(0\)\
\-\ cigarteet\\:\\ 0\\.018998962120617455\ \(0\)\
\-\ diseasese\\:\\ 0\\.018998962120617455\ \(0\)\
\-\ legg\\-calvep\\-perthe\\:\\ 0\\.018998962120617455\ \(0\)\
\-\ sarcoid\\:\\ 0\\.018899575970358552\ \(0\)\
\-\ diseases\\:\\ 0\\.018554564299351935\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.018279342437341015\ \(0\)\
\-\ replacement\\:\\ 0\\.01797899795183244\ \(0\)\
\-\ t1\\:\\ 0\\.01751182458765675\ \(0\)\
\-\ hemoglobinopathies\\:\\ 0\\.01750511043837619\ \(0\)\
\-\ hypercortisolism\\:\\ 0\\.01750511043837619\ \(0\)\
\-\ fluticasone\\:\\ 0\\.01750511043837619\ \(0\)\
\-\ short\\:\\ 0\\.01736218397062264\ \(0\)\
\-\ received\\:\\ 0\\.01711780748925822\ \(0\)\
\-\ ring\\:\\ 0\\.01711780748925822\ \(0\)\
\-\ demonstrate\\:\\ 0\\.016952173632181385\ \(0\)\
\-\ joints\\:\\ 0\\.016854498472103744\ \(0\)\
\-\ total\\:\\ 0\\.015860862012569983\ \(0\)\
\-\ \\,\\:\\ 0\\.015752525364152496\ \(0\)\
\-\ t2\\:\\ 0\\.015637427384161757\ \(0\)\
\-\ recurrent\\:\\ 0\\.01554324254795292\ \(0\)\
\-\ fabry\\:\\ 0\\.01553034593002672\ \(0\)\
\-\ frog\\:\\ 0\\.015137411540384576\ \(0\)\
\-\ signal\\:\\ 0\\.014567290928487794\ \(0\)\
\-\ caisson\\:\\ 0\\.014517407073893668\ \(0\)\
\-\ hld\\:\\ 0\\.01426356432463422\ \(0\)\
\-\ bouts\\:\\ 0\\.01426356432463422\ \(0\)\
\-\ attacks\\:\\ 0\\.013831084377517516\ \(0\)\
\-\ pt\\:\\ 0\\.013694671356175657\ \(0\)\
\-\ osteotomy\\:\\ 0\\.013643559858143313\ \(0\)\
\-\ hemodialysis\\:\\ 0\\.013643559858143313\ \(0\)\
\-\ intensity\\:\\ 0\\.01331323567404871\ \(0\)\
\-\ associated\\:\\ 0\\.013037473460610141\ \(0\)\
\-\ gaucher\\:\\ 0\\.013023555391652406\ \(0\)\
\-\ vast\\:\\ 0\\.01276971264239296\ \(0\)\
\-\ scfe\\:\\ 0\\.012653188458620814\ \(0\)\
\-\ arthroplasty\\:\\ 0\\.012542642565544196\ \(0\)\
\-\ longstanding\\:\\ 0\\.012241431482839113\ \(0\)\
\-\ grafting\\:\\ 0\\.012241431482839113\ \(0\)\
\-\ arteritis\\:\\ 0\\.012241431482839113\ \(0\)\
\-\ untreated\\:\\ 0\\.012149708175902052\ \(0\)\
\-\ bilaterally\\:\\ 0\\.012097867407430617\ \(0\)\
\-\ link\\:\\ 0\\.011977202340398741\ \(0\)\
\-\ revealed\\:\\ 0\\.011821008145974539\ \(0\)\
\-\ unclear\\:\\ 0\\.01174185903875005\ \(0\)\
\-\ such\\:\\ 0\\.01151436547345195\ \(0\)\
\-\ during\\:\\ 0\\.011271591594499173\ \(0\)\
\-\ some\\:\\ 0\\.011185035577011893\ \(0\)\
\-\ sle\\:\\ 0\\.010995574045823686\ \(0\)\
\-\ prednisone\\:\\ 0\\.010892927388519257\ \(0\)\
\-\ decade\\:\\ 0\\.010843381013034992\ \(0\)\
\-\ his\\:\\ 0\\.010615900981236775\ \(0\)\
\-\ infiltrative\\:\\ 0\\.010567878057194724\ \(0\)\
\-\ collagen\\:\\ 0\\.010483350658157479\ \(0\)\
\-\ ttp\\:\\ 0\\.010442298513824088\ \(0\)\
\-\ gout\\:\\ 0\\.01032363520092963\ \(0\)\
\-\ core\\:\\ 0\\.010211165905303403\ \(0\)\
\-\ future\\:\\ 0\\.010211165905303403\ \(0\)\
\-\ 49\\:\\ 0\\.010211165905303403\ \(0\)\
\-\ fifth\\:\\ 0\\.010104275945951308\ \(0\)\
\-\ pancreatitis\\:\\ 0\\.010104275945951308\ \(0\)\
\-\ standing\\:\\ 0\\.009812152040787031\ \(0\)\
\-\ mild\\:\\ 0\\.009699368335910072\ \(0\)\
\-\ is\\:\\ 0\\.009694668592840096\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.00966548509413829\ \(0\)\
\-\ african\\:\\ 0\\.009609503442407127\ \(0\)\
\-\ that\\:\\ 0\\.009542978848440667\ \(0\)\
\-\ walking\\:\\ 0\\.009449787985179276\ \(0\)\
\-\ both\\:\\ 0\\.009406034442612591\ \(0\)\
\-\ smoking\\:\\ 0\\.009301096451802228\ \(0\)\
\-\ alcohol\\:\\ 0\\.009277282149675967\ \(0\)\
\-\ patient\\:\\ 0\\.009230516496943836\ \(0\)\
\-\ disease\\:\\ 0\\.00903063065441188\ \(0\)\
\-\ pain\\:\\ 0\\.008996622133885643\ \(0\)\
\-\ options\\:\\ 0\\.008948446831582826\ \(0\)\
\-\ 55\\:\\ 0\\.008928210322208172\ \(0\)\
\-\ fourth\\:\\ 0\\.008908162062160083\ \(0\)\
\-\ potential\\:\\ 0\\.00886861650468552\ \(0\)\
\-\ giant\\:\\ 0\\.00886861650468552\ \(0\)\
\-\ american\\:\\ 0\\.00877281529224838\ \(0\)\
\-\ our\\:\\ 0\\.00875415567426753\ \(0\)\
\-\ steroids\\:\\ 0\\.008663206634417579\ \(0\)\
\-\ recently\\:\\ 0\\.008593113548845253\ \(0\)\
\-\ most\\:\\ 0\\.008503599748827913\ \(0\)\
\-\ mri\\:\\ 0\\.00846239592635612\ \(0\)\
\-\ local\\:\\ 0\\.008459416585656777\ \(0\)\
\-\ idiopathic\\:\\ 0\\.008395554952884425\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.00831830035854577\ \(0\)\
\-\ report\\:\\ 0\\.008243719476697763\ \(0\)\
\-\ there\\:\\ 0\\.008222298856454669\ \(0\)\
\-\ even\\:\\ 0\\.00820017915920311\ \(0\)\
\-\ life\\:\\ 0\\.00803431484640973\ \(0\)\
\-\ pregnancy\\:\\ 0\\.007917790662637581\ \(0\)\
\-\ intermittent\\:\\ 0\\.007905224024036735\ \(0\)\
\-\ stage\\:\\ 0\\.00785567764855247\ \(0\)\
\-\ suggest\\:\\ 0\\.007843467007311786\ \(0\)\
\-\ oral\\:\\ 0\\.0077598764361153285\ \(0\)\
\-\ coronal\\:\\ 0\\.007668153129178269\ \(0\)\
\-\ i\\:\\ 0\\.007612747187992478\ \(0\)\
\-\ films\\:\\ 0\\.007601834899293024\ \(0\)\
\-\ occurs\\:\\ 0\\.0075587300141493384\ \(0\)\
\-\ upon\\:\\ 0\\.007526957855232952\ \(0\)\
\-\ treatment\\:\\ 0\\.007455245515521064\ \(0\)\
\-\ includes\\:\\ 0\\.0074243111979285245\ \(0\)\
\-\ and\\:\\ 0\\.0073710584243796345\ \(0\)\
\-\ conservative\\:\\ 0\\.007355260866582367\ \(0\)\
\-\ use\\:\\ 0\\.007278963610007118\ \(0\)\
\-\ worsening\\:\\ 0\\.007251034418967237\ \(0\)\
\-\ leg\\:\\ 0\\.00724180454441551\ \(0\)\
\-\ failure\\:\\ 0\\.007214349747481394\ \(0\)\
\-\ management\\:\\ 0\\.0069494212143440546\ \(0\)\
\-\ appears\\:\\ 0\\.006855019010338898\ \(0\)\
\-\ congenital\\:\\ 0\\.006735256400091461\ \(0\)\
\-\ did\\:\\ 0\\.0066496091400709565\ \(0\)\
\-\ required\\:\\ 0\\.006628718775403586\ \(0\)\
\-\ for\\:\\ 0\\.006285415074506165\ \(0\)\
\-\ on\\:\\ 0\\.0062404397617709315\ \(0\)\
\-\ cause\\:\\ 0\\.006231169453775789\ \(0\)\
\-\ this\\:\\ 0\\.006214249224013791\ \(0\)\
\-\ possible\\:\\ 0\\.006202547885526017\ \(0\)\
\-\ areas\\:\\ 0\\.006196868903547557\ \(0\)\
\-\ cases\\:\\ 0\\.006135368241338647\ \(0\)\
\-\ along\\:\\ 0\\.00608632301047094\ \(0\)\
\-\ vascular\\:\\ 0\\.006038369111904519\ \(0\)\
\-\ several\\:\\ 0\\.00592045869767756\ \(0\)\
\-\ superior\\:\\ 0\\.005880913140202998\ \(0\)\
\-\ often\\:\\ 0\\.005876020578706147\ \(0\)\
\-\ between\\:\\ 0\\.005837274862552249\ \(0\)\
\-\ frontal\\:\\ 0\\.005785111927765856\ \(0\)\
\-\ as\\:\\ 0\\.005571454766785034\ \(0\)\
\-\ renal\\:\\ 0\\.005533352477280321\ \(0\)\
\-\ primary\\:\\ 0\\.005455569532102794\ \(0\)\
\-\ years\\:\\ 0\\.005407851588401902\ \(0\)\
\-\ of\\:\\ 0\\.005272801329219304\ \(0\)\
\-\ abnormal\\:\\ 0\\.005252353966195929\ \(0\)\
\-\ head\\:\\ 0\\.005223278686581672\ \(0\)\
\-\ edema\\:\\ 0\\.005208886830670886\ \(0\)\
\-\ chronic\\:\\ 0\\.005187477657127155\ \(0\)\
\-\ include\\:\\ 0\\.00516627906903079\ \(0\)\
\-\ secondary\\:\\ 0\\.005148771479544844\ \(0\)\
\-\ he\\:\\ 0\\.005138334788864266\ \(0\)\
\-\ however\\:\\ 0\\.005127948395683341\ \(0\)\
\-\ low\\:\\ 0\\.005121051838074137\ \(0\)\
\-\ history\\:\\ 0\\.0050871316280477735\ \(0\)\
\-\ high\\:\\ 0\\.005039969959217275\ \(0\)\
\-\ trauma\\:\\ 0\\.005036656857236916\ \(0\)\
\-\ one\\:\\ 0\\.004990800395066043\ \(0\)\
\-\ cell\\:\\ 0\\.004974656705994582\ \(0\)\
\-\ \\:\\:\\ 0\\.004871874206856315\ \(0\)\
\-\ common\\:\\ 0\\.004819541405078442\ \(0\)\
\-\ these\\:\\ 0\\.004792768732667759\ \(0\)\
\-\ bone\\:\\ 0\\.004576367847973857\ \(0\)\
\-\ physical\\:\\ 0\\.004518330322373358\ \(0\)\
\-\ the\\:\\ 0\\.004469265669298248\ \(0\)\
\-\ without\\:\\ 0\\.004336235272323621\ \(0\)\
\-\ or\\:\\ 0\\.004316908400705636\ \(0\)\
\-\ \\%\\:\\ 0\\.004295950502900879\ \(0\)\
\-\ a\\:\\ 0\\.004273704760976307\ \(0\)\
\-\ small\\:\\ 0\\.0042426191473731\ \(0\)\
\-\ \\'s\\:\\ 0\\.004060445298204839\ \(0\)\
\-\ exam\\:\\ 0\\.004045762801615384\ \(0\)\
\-\ case\\:\\ 0\\.0040291043811794625\ \(0\)\
\-\ have\\:\\ 0\\.003988013099924767\ \(0\)\
\-\ had\\:\\ 0\\.003973814265604975\ \(0\)\
\-\ presents\\:\\ 0\\.003762164429973978\ \(0\)\
\-\ has\\:\\ 0\\.0034584051088238747\ \(0\)\
\-\ male\\:\\ 0\\.0033301843488954164\ \(0\)\
\-\ be\\:\\ 0\\.0028399929382412264\ \(0\)\
\-\ from\\:\\ 0\\.002729387312832354\ \(0\)\
\-\ in\\:\\ 0\\.002724551056941303\ \(0\)\
\-\ are\\:\\ 0\\.0025105040356241414\ \(0\)\
\-\ with\\:\\ 0\\.002269477553467689\ \(0\)\
\-\ was\\:\\ 0\\.002129908453046739\ \(0\)\
\-\ left\\:\\ 0\\.002060571701019213\ \(0\)\
\-\ year\\:\\ 0\\.002060571701019213\ \(0\)\
\-\ right\\:\\ 0\\.001943171786875898\ \(0\)\
\-\ old\\:\\ 0\\.0018856349070307211\ \(0\)\
\-\ no\\:\\ 0\\.0018544054972064697\ \(0\)\
\-\ to\\:\\ 0\\.001840810812254251\ \(0\)\
\-\ \\.\\:\\ 0\\.0018361829015868763\ \(0\)\
